Asklepios BioPharmaceutical, Inc. Enters Cross-License Agreement With Genzyme Corporation
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Asklepios BioPharmaceutical, Inc. (AskBio) today announced that it has entered into a non-exclusive cross-license agreement with Genzyme, a Sanofi company, in which Genzyme receives rights to AskBio’s Duplex gene therapy vector technology for its internal product development and external sublicensing.
Help employers find you! Check out all the jobs and post your resume.
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Asklepios BioPharmaceutical, Inc. (AskBio) today announced that it has entered into a non-exclusive cross-license agreement with Genzyme, a Sanofi company, in which Genzyme receives rights to AskBio’s Duplex gene therapy vector technology for its internal product development and external sublicensing.
Help employers find you! Check out all the jobs and post your resume.